Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, 845 19th St South, BBRB 206, Birmingham, AL, 35205, USA.
Division of Infectious Diseases, School of Medicine, University of Colorado-AMC, Aurora, CO, USA.
Drugs. 2020 Apr;80(6):535-545. doi: 10.1007/s40265-020-01284-1.
Long-acting antiretroviral therapy holds the promise of new options for human immunodeficiency virus (HIV) treatment beyond the current paradigm of daily oral pills. Of particular interest is their potential role in addressing challenges with adherence to oral therapy and treatment fatigue. Similar to other conditions where long-acting formulations have proven effective such as contraception and mental health, long-acting antiretroviral therapy could provide additional treatment choices to people with HIV. This review provides an outline of the current landscape of long-acting antiretroviral therapy for HIV treatment, both approved and under development, including cabotegravir, rilpivirine, leronlimab, islatravir, albuvirtide, GS-6207, and broadly neutralizaing antibodies. However, there are a number of research gaps for long-acting antiretroviral therapy including issues regarding resistance and understudied populations, and this review highlights some of the challenges that will need to be addressed for clinical implementation of these novel treatment modalities.
长效抗逆转录病毒疗法有望为人类免疫缺陷病毒 (HIV) 治疗提供超越当前每日口服药物治疗模式的新选择。特别值得关注的是，它们在解决口服治疗依从性和治疗疲劳方面的挑战方面的潜在作用。类似于其他已被证明有效的长效制剂领域，如避孕和心理健康，长效抗逆转录病毒疗法可以为 HIV 感染者提供更多的治疗选择。这篇综述概述了目前批准和正在开发的长效抗逆转录病毒疗法在 HIV 治疗中的应用，包括卡替拉韦、利匹韦林、来仑替拉韦、依发韦仑、阿巴卡韦、GS-6207 和广谱中和抗体。然而，长效抗逆转录病毒疗法还存在许多研究空白，包括耐药性和研究不足人群的问题，本综述强调了在这些新型治疗方式的临床应用中需要解决的一些挑战。
